Additional information concerning these and other risk factors, in the Annual Report in the Annual Report on Form 10 – K Anesiva for the year ended December 2007 and last quarterly report on Form 10-Q.. Forward-Looking StatementsThis press release includes ‘forward-looking statements ‘within the meaning of safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as ‘expect,”estimate,”project,”budget,”forecast,”anticipate,”intend,”plan,”may,”could,”should,”believes,”predicts,”potential,”continue ‘and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that could cause the actual results, performance or achievements to differ significantly from those expressed or implied by this press release.
In clinical trials, the common side effects Zingo redness , red dots and swelling . The next product in Anesiva pipeline, Adlea , is currently in two Phase 3 trials an indication for the an indication for the treatment of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks months. In multiple settings in mid stage clinical trials for site-specific, acute and chronic, moderate-to – severe pain Anesiva is based in South San Francisco, California.Mr. Victor Chong: Mr. Victor Chong is consultant Ophthalmic Surgeon and Head of Laser and Retinal Research Unit at Kings College Hospital, and Honorary Senior Lecturer in at King’s College London and the Institute of Ophthalmology Board, University College London. He is the head of the regional macula Services for South East London and West Kent.
Which Results The can be expected? Treatment results are good. After treatment, patient 90-95 percent disease stabilization and 30-40 percent Reports experience visual enhancement.
Treatment – Optical aids on dry AMD can – Drug Treatments – laser Treatment – Visudyne Avastin Lucentis is Macugen can photodynamic therapy .